



21 July 2023

First quarter performance update

Blis Technologies Limited (Blis) delivers revenue growth of 18% and a break-even EBITDA result for the first quarter ending 30 June 2023 (unaudited).

Revenue for the three months to 30 June 2023 was \$2.8m, an increase of \$0.4m compared with the same period last year. EBITDA was breakeven \$0.0m compared with a loss of \$0.3m in the same period last year.

“Following a profitable second half of FY23, we are pleased to start the year with a break-even quarter in line with our expectations. The first quarter revenue growth is from our B2B business, with an increase in Probi royalties and a lift in US ingredient sales for the quarter. Our B2C revenue for the quarter was similar to the same period last year.”

“We continue to see the refreshed strategy and business model drive revenue growth and support our journey back to profitability.” said Brian Watson CEO.

Ends

For further information, please contact:

Brian Watson
CEO
+64 27 705 9133

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics